This is also supported by previous work with CDK inhibitors in lung [38,39] or breast cancer cells [40,41,42], where cells with developed resistance to CDK inhibitors present a limited response to these compounds, with minimal inhibition of the cell cycle progression and elevated CDK4 or 6 expressions. This evidence concerns the gene CDK4 and breast carcinoma.